In this complimentary 30-minute webinar on Thursday 9 April, 2026, our specialists Sabera Hyderally, Head of US MedTech and Kristin Lovallo, Director, will share how this advanced methodology can uncover deeper insights, helping organizations prioritize product features, refine value propositions, and make more confident strategic decisions.

We are delighted to be attending the ACC Annual Conference from March 28–30 in New Orleans, Louisiana. Senior Research Executives Molly Hines and Supreet Kaur will be representing Purdie Pascoe at the event.

We are delighted to be attending the SAGES Annual Conference from March 25–28 in Tampa, Florida. Kristin Lovallo, US Research Director, will be representing Purdie Pascoe at the event.

The 2026 MedTech Clinical Network Conference, hosted by TT Life Sciences in Brussels, brought together clinical leaders from across Europe at a pivotal time for the MedTech sector. Rather than simply revisiting regulatory updates, this year’s discussions focused on a broader challenge: how organisations can navigate uncertainty, strengthen clinical strategy, and generate evidence that delivers both regulatory assurance and commercial value.

Find out how we used a staged qualitative approach to help our client understand the landscape of digital solutions in GI endotherapy with a focus on AI, data management (clinical and non-clinical), workflow, and supply management.

It already feels like we’re flying through 2026, and the next wave of major MedTech conferences is coming into view fast. Calendars are filling, budgets are being committed, and plans are taking shape. The question is no longer whether to attend, but whether your conference research strategy is truly ready?

Real-World Evidence (RWE) is playing an increasingly important role in global MedTech regulatory decision-making, supporting evidence generation across the product lifecycle, from pre-market submissions to post-market surveillance. Watch this webcast which features industry experts to understand how MedTech manufacturers can build effective, compliant RWE strategies.

As the ctDNA cancer monitoring market becomes increasingly competitive, established panels continue to maintain their foothold amidst a surge of new entrants. Purdie Pascoe is conducting an ongoing syndicated study exploring the US ctDNA Cancer Monitoring Landscape. Waves 1 through 4 are now available for immediate purchase.

Our primary market research team combines deep expertise with a full range of qualitative and quantitative techniques, including the latest digital approaches with a wealth of experience across medical devices, digital healthcare, drug delivery, precision medicine and diagnostics.

As part of compliance with the EU Medical Device Regulation (MDR), the manufacturer of a Class III guidewire needed to generate robust Post Market Clinical Follow-Up (PMCF) data to confirm ongoing safety and performance. The study was designed to evaluate two key endpoints: procedural success, and freedom from adverse events.

Innovation sits right at the intersection of data, technology, and research. Our Innovation team’s goal is simple: make complex studies easier to run, insights easier to find, and decisions easier to make, for both our research colleagues and our clients.

As regulators worldwide including the FDA and EU Notified Bodies place greater emphasis on RWD, the industry faces a familiar but intensified challenge: how to generate high-quality, device-specific evidence efficiently, reliably, and without escalating costs. That’s where Post-Market Surveys come in.

As we approach the end of 2025, the global Purdie Pascoe team wishes you a relaxing and fun holiday season with your loved ones. It has been a big year for us, from reaffirming our MedTech positioning and elevating our brand, to partnering with a range of existing and new clients across both our Primary Market Research and Post Market Survey teams. We’ve achieved all of this while having fun, staying true to our close-knit culture, and experiencing our biggest year of growth to date…

Have you ever wondered what really makes your employees tick when it comes to their health and wellbeing? What drives them to move, eat well, switch off mentally or what silently holds them back? Each November, millions join Movember to spark conversation and action around men’s physical and mental health. At Purdie Pascoe, we’ve taken part for the last few years. But this year, we wanted to go a step further. Instead of just looking outward, we turned the lens on ourselves.

As we all start to get into the festive spirit ahead of the holiday season, it’s a perfect time to reflect on achievements, and of course challenges across the past year. 2025 has been a big year for Purdie Pascoe, and in this short interview, Co-Founder Guy Pascoe provides insight into what has made this year so pivotal for the business.

SABCS is one of the world’s most influential scientific meetings dedicated to breast cancer research and treatment. Are you attending? Meet Parisa Valadan, Associate Director to discuss how our team can help you clarify your strategy and uncover opportunities to accelerate impact.

Our dedicated division has evolved. While PMCF remains a core part of our offering, we’re now applying our expertise to broader areas, including other forms of Real World Data (RWD) collection and Post Market Performance Follow-Up (PMPF). In this conversation, Marcus and Ellie discuss the why behind the expansion of our services, the evolution of the team, and what it means for our clients at Purdie Pascoe.

Beneath the white coats, doctors are still human. They respond to good stories, authentic visuals, and messages that feel credible and relevant.  At Purdie Pascoe, ad testing continues to be one of the most revealing parts of our work, helping medical device manufacturers understand not just what their audiences say they want, but what they actually respond to.

In this piece, Marcus Torr, Head of Post Market Surveys, shares his reflections on the discussions shaping the regulatory landscape, the themes emerging across both events, and how continued collaboration can drive meaningful improvements in patient safety and lifecycle management.

Imagine a simple blood test that could screen for dozens of cancers, long before symptoms appear. This is the promise of Multi-Cancer Early Detection (MCED), a rapidly emerging field that has the potential to transform how we approach cancer screening globally. As with any breakthrough, the success of MCED will depend not only on the science, but also on public awareness, understanding and interest, healthcare system readiness, and equitable access.